Non-Aβ, Non-Tau Drugs Tweak Markers, Cognition in Alzheimer’s, Huntington’s
Researchers at the online AAT-AD/PD meeting touted therapies that target neuroinflammation, synapses, epigenetic regulation, or the cortisol stress response.
6471 RESULTS
Sort By:
Researchers at the online AAT-AD/PD meeting touted therapies that target neuroinflammation, synapses, epigenetic regulation, or the cortisol stress response.
AI-powered apps catch changes in how a person speaks that may reveal cognitive decline in frontotemporal dementia and early Alzheimer’s. Can smartphones deliver biomarkers for trial enrollment and diagnosis?
The ICAD featured that the interest in small Aβ aggregates has branched out far beyond the initial debates about whether they even exist and which forms are important...
Clinical validation is showing automated Elecsys, Lumipulse assays to be reliable and predictive. The story on blood tests has turned from non-starter to intensely promising for broad-based screening.
Large IDEAS data set establishes that PET scans are valuable in clinical practice. Other studies suggest CSF biomarker ratios perform nearly as well.
African Americans carrying a variant in a cholesterol-processing gene have double the risk for Alzheimer’s than non-carriers...
New genes linked to early and late-onset AD offer up mechanistic insight, potential targets for treatment.
Antisense oligonucleotides are raising hopes for tackling a wide range of brain disorders—is the enthusiasm warranted?
Digital Biomarkers of FTD: How to Move from Tech Tinkering to Trials? Digital Tools Abound, Yet Remote Biomarkers for FTD Remain Exploratory Changes in activity, speech, sleep, or the way a person moves are all examples of measurements that can be capture
The interplay between glia and Aβ is one aspect of AD pathology that continues to mystify...
A spate of recent studies could not replicate the finding that knocking down the RNA-binding protein PTBP1 in astrocytes triggers their conversion to neurons. Leaky expression of the knockdown construct in endogenous neurons may be to blame.
Cognitively normal people whose PET scans showed both plaques and tangles slid toward MCI or dementia within a few years. This risk was 19 times higher than in people without these deposits.
In wake of Medicare coverage decision, Biogen jettisons aducanumab sales staff but keeps trials going. Eisai/Biogen wrap up accelerated approval application to U.S. regulators.
With its affinity for β-sheets, a probe called Capture Molecule for Amyloid Precipitation, aka CAP-1, pulls α-synuclein and other soluble amyloids out of solution.
Advances in microscopy yield unprecedented views of Aβ plaques in vivo and ex vivo. The vistas offer new insights about how plaques form, grow, and clear.